EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma

Jens Tijtgat iD, Xenia Geeraerts, Anais Boisson, Latoya Stevens, Manon Vounckx, Iris Dirven, Julia Katharina Schwarze iD, Steven Raeymaeckers, Ramses Forsyth, Ivan Van Riet, Sandra Tuyaerts iD, Karen Willard-Gallo und 1 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-008148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Jens Tijtgat und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology/Laboratory for Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB)/Universitair Ziekenhuis Brussel…. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek, Kom op tegen Kanker.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with advanced melanoma who progress after treatment with immune checkpoint-inhibitors (ICI) and BRAF-/MEK-inhibitors (if BRAF V600 mutated) have no remaining effective treatment options. The presence of CD1c (BDCA-1) + and CD141 (BDCA-3) + myeloid dendritic cells (myDC) in the tumor microenvironment correlates with pre-existing immune recognition and responsiveness to immune checkpoint blockade. The synthetic saponin-based immune adjuvant AS01 B enhances adaptive immunity through the involvement of myDC.

Methods

In this first-in-human phase I clinical trial, patients with metastatic melanoma refractory to ICI and BRAF-/MEK inhibitors (when indicated) were recruited. Patients received an intravenous administration of low-dose nivolumab (10 mg, every 2 weeks) plus an intratumoral (IT) administration of 10 mg ipilimumab and 50 µg (0.5 mL) AS01 B (every 2 weeks). All myDC, isolated from blood, were injected on day 2 into the same metastatic lesion. Tumor biopsies and blood samples were collected at baseline and repeatedly on treatment. Multiplex immunohistochemistry (mIHC) was performed on biopsy sections to characterize and quantify the IT and peritumoral immune cell composition.

Results

Study treatment was feasible and well tolerated without the occurrence of unexpected adverse events in all eight patients. Four patients (50%) obtained a complete response (CR) in the injected lesions. Of these, two patients obtained an overall CR, and one patient a partial response. All responses are ongoing after more than 1 year of follow-up. One additional patient had a stable disease as best response. The disease control rate was 50%. Median progression-free survival and overall survival were 24.1 and 41.9 weeks, respectively. Baseline tumor biopsies from patients who responded to treatment had features of T-cell exclusion. During treatment, there was an increased T-cell infiltration, with a reduced mean distance between T cells and tumor cells. Peripheral blood immune cell composition did not significantly change during study treatment.

Conclusions

Combining an intratumoral injection of CD1c (BDCA-1) + and CD141 (BDCA-3) + myDC with repeated IT administration of ipilimumab and AS01 B and systemic low-dose nivolumab is safe, feasible with promising early results, worthy of further clinical investigation. Trial registration number ClinicalTrials.gov identifier NCT03707808 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaHumansNivolumabIpilimumabAdjuvants, ImmunologicProto-Oncogene Proteins B-rafAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsAdministration, IntravenousMitogen-Activated Protein Kinase KinasesTumor Microenvironment

Stichwörter der Autor:innen

Adjuvants, ImmunologicDendritic CellsImmunohistochemistryMelanomaTherapies, Investigational

Substanzen

NivolumabIpilimumabAdjuvants, ImmunologicProto-Oncogene Proteins B-rafAntibodies, MonoclonalMitogen-Activated Protein Kinase Kinases

Autor:innen und Institutionen

  • Department of Medical Oncology/Laboratory for Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB)/Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • Molecular Immunology Unit (MIU), Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Department of Radiology, Vrije Universiteit Brussel (VUB)/Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • Department of Pathology, Vrije Universiteit Brussel (VUB)/Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • Department of Hematology, Stem Cell Laboratory, Vrije Universiteit Brussel (VUB)/Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
  • Department of Medical Oncology/Laboratory for Medical and Molecular Oncology (LMMO), Vrije Universiteit Brussel (VUB)/Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium bart.neyns@uzbrussel.be.

ORCID-Profile: Jens Tijtgat, Julia Katharina Schwarze, Sandra Tuyaerts, Bart Neyns

Förderung

  • Fonds Wetenschappelijk Onderzoek
  • Kom op tegen Kanker

Zitieren

APA

Tijtgat, J., Geeraerts, X., Boisson, A., Stevens, L., Vounckx, M., Dirven, I., Schwarze, J. K., Raeymaeckers, S., Forsyth, R., Van Riet, I., Tuyaerts, S., Willard-Gallo, K., & Neyns, B. (2024). Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008148

Vancouver

Tijtgat J, Geeraerts X, Boisson A, Stevens L, Vounckx M, Dirven I, et al. Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008148

BibTeX
@article{Tijtgat2024,
  author = {Tijtgat, Jens and Geeraerts, Xenia and Boisson, Anais and Stevens, Latoya and Vounckx, Manon and Dirven, Iris and Schwarze, Julia Katharina and Raeymaeckers, Steven and Forsyth, Ramses and Van Riet, Ivan and Tuyaerts, Sandra and Willard-Gallo, Karen and Neyns, Bart},
  title = {Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-008148}
}
Kostenlos starten →